211 related articles for article (PubMed ID: 9756165)
1. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ
Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas.
Schraffordt Koops H; Eggermont AM; Liénard D; Kroon BB; Hoekstra HJ; Van Geel AN; Nieweg OE; Lejeune FJ
Semin Surg Oncol; 1998; 14(3):210-4. PubMed ID: 9548603
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I
Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma.
Olieman AF; Pras E; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):807-14. PubMed ID: 9531364
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.
Bonvalot S; Rimareix F; Causeret S; Le Péchoux C; Boulet B; Terrier P; Le Cesne A; Muret J
Ann Surg Oncol; 2009 Dec; 16(12):3350-7. PubMed ID: 19830495
[TBL] [Abstract][Full Text] [Related]
7. The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.
Schwindenhammer B; Podleska LE; Kutritz A; Bauer S; Sheu SY; Taeger G; Schmid KW; Grabellus F
World J Surg Oncol; 2013 Aug; 11(1):185. PubMed ID: 23938063
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
[TBL] [Abstract][Full Text] [Related]
9. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Komdeur R; Plaat BE; Hoekstra HJ; Molenaar WM; Hollema H; van den Berg E; Mastik MF; van der Graaf WT
Cancer; 2001 May; 91(10):1940-8. PubMed ID: 11346877
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience.
Rastrelli M; Campana LG; Valpione S; Tropea S; Zanon A; Rossi CR
Int J Hyperthermia; 2016; 32(2):165-72. PubMed ID: 26608883
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic isolated limb perfusion in the management of extremity sarcoma.
Hoekstra HJ; van Ginkel RJ
Curr Opin Oncol; 2003 Jul; 15(4):300-3. PubMed ID: 12874508
[TBL] [Abstract][Full Text] [Related]
12. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan.
Lev-Chelouche D; Abu-Abeid S; Kollander Y; Meller I; Isakov J; Merimsky O; Klausner JM; Gutman M
J Surg Oncol; 1999 Mar; 70(3):185-9. PubMed ID: 10102350
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
[TBL] [Abstract][Full Text] [Related]
14. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
17. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities.
Grünhagen DJ; de Wilt JH; van Geel AN; Verhoef C; Eggermont AM
Recent Results Cancer Res; 2009; 179():257-70. PubMed ID: 19230545
[TBL] [Abstract][Full Text] [Related]
18. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
[TBL] [Abstract][Full Text] [Related]
19. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity.
Bickels J; Manusama ER; Gutman M; Eggermont AM; Kollender Y; Abu-Abid S; Van Geel AN; Lev-Shlush D; Klausner JM; Meller I
Eur J Surg Oncol; 1999 Oct; 25(5):509-14. PubMed ID: 10527599
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]